HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $66 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating for Mirum Pharmaceuticals, maintaining a price target of $66.
October 11, 2024 | 10:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Mirum Pharmaceuticals, maintaining a price target of $66, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $66 price target by a reputable analyst suggests a positive outlook for Mirum Pharmaceuticals. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100